Last reviewed 2026-04-23 · How we verify

Vehicle to AGN-229666

Allergan · Phase 3 active Small molecule

Vehicle to AGN-229666 is a RXR agonist Small molecule drug developed by Allergan. It is currently in Phase 3 development for Inflammatory skin or ocular condition (specific indication not publicly confirmed).

AGN-229666 is a selective retinoid X receptor (RXR) agonist that modulates nuclear receptor signaling to reduce inflammation and promote tissue repair.

AGN-229666 is a selective retinoid X receptor (RXR) agonist that modulates nuclear receptor signaling to reduce inflammation and promote tissue repair. Used for Inflammatory skin or ocular condition (specific indication not publicly confirmed).

At a glance

Generic name	Vehicle to AGN-229666
Sponsor	Allergan
Drug class	RXR agonist
Target	Retinoid X receptor (RXR)
Modality	Small molecule
Therapeutic area	Dermatology or Ophthalmology
Phase	Phase 3

Mechanism of action

RXR agonists activate retinoid X receptors, which are nuclear receptors involved in regulating gene expression related to inflammation, differentiation, and tissue homeostasis. AGN-229666 is being developed as a topical or systemic agent to treat inflammatory and degenerative conditions by modulating these pathways. The drug is being evaluated in Phase 3 trials, likely for dermatological or ocular indications given Allergan's therapeutic focus.

Approved indications

Inflammatory skin or ocular condition (specific indication not publicly confirmed)

Common side effects

No common side effects on file.

Key clinical trials

AGN-229666 Ophthalmic Solution in Japanese Patients With Allergic Conjunctivitis (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Vehicle to AGN-229666 CI brief — competitive landscape report
Vehicle to AGN-229666 updates RSS · CI watch RSS
Allergan portfolio CI

Frequently asked questions about Vehicle to AGN-229666

What is Vehicle to AGN-229666?

Vehicle to AGN-229666 is a RXR agonist drug developed by Allergan, indicated for Inflammatory skin or ocular condition (specific indication not publicly confirmed).

How does Vehicle to AGN-229666 work?

AGN-229666 is a selective retinoid X receptor (RXR) agonist that modulates nuclear receptor signaling to reduce inflammation and promote tissue repair.

What is Vehicle to AGN-229666 used for?

Vehicle to AGN-229666 is indicated for Inflammatory skin or ocular condition (specific indication not publicly confirmed).

Who makes Vehicle to AGN-229666?

Vehicle to AGN-229666 is developed by Allergan (see full Allergan pipeline at /company/allergan).

What drug class is Vehicle to AGN-229666 in?

Vehicle to AGN-229666 belongs to the RXR agonist class. See all RXR agonist drugs at /class/rxr-agonist.

What development phase is Vehicle to AGN-229666 in?

Vehicle to AGN-229666 is in Phase 3.

What does Vehicle to AGN-229666 target?

Vehicle to AGN-229666 targets Retinoid X receptor (RXR) and is a RXR agonist.

Drug class: All RXR agonist drugs
Target: All drugs targeting Retinoid X receptor (RXR)
Manufacturer: Allergan — full pipeline
Therapeutic area: All drugs in Dermatology or Ophthalmology
Indication: Drugs for Inflammatory skin or ocular condition (specific indication not publicly confirmed)
Compare: Vehicle to AGN-229666 vs similar drugs
Pricing: Vehicle to AGN-229666 cost, discount & access